A phase 2 study showed a 93.3% objective response rate for lenvatinib and tislelizumab in FH-RCC patients, with a 20% complete response rate. FH-RCC is driven by FH gene mutations, leading to early ...
Adjuvant everolimus does not improve recurrence-free or overall survival in patients with papillary and chromophobe subtypes of non–clear cell renal cell carcinoma (RCC) and is associated with higher ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback